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Objective: To describe the clinical spectrum of cryoglobulinemic vasculitis (CV) in primary Sj€ogren’s syndrome
(pSS), investigate its relation to lymphoma and identify the differences with hepatitis C virus (HCV) related CV.
Methods: From a multicentre study population of consecutive pSS patients, those who had been evaluated for
cryoglobulins and fulfilled the 2011 classification criteria for CV were identified retrospectively. pSS-CV patients
were matched with pSS patients without cryoglobulins (1:2) and HCV-CV patients (1:1). Clinical, laboratory and
outcome features were analyzed. A data driven logistic regression model was applied for pSS-CV patients and
their pSS cryoglobulin negative controls to identify independent features associated with lymphoma.
Results: 1083 pSS patients were tested for cryoglobulins. 115 (10.6%) had cryoglobulinemia and 71 (6.5%) ful-
filled the classification criteria for CV. pSS-CV patients had higher frequency of extraglandular manifestations
and lymphoma (OR=9.87, 95% CI: 4.720.9) compared to pSS patients without cryoglobulins. Purpura was
the commonest vasculitic manifestation (90%), presenting at disease onset in 39% of patients. One third of
pSS-CV patients developed B-cell lymphoma within the first 5 years of CV course, with cryoglobulinemia
being the strongest independent lymphoma associated feature. Compared to HCV-CV patients, pSS-CV indi-
viduals displayed more frequently lymphadenopathy, type II IgMk cryoglobulins and lymphoma (OR = 6.12,
95% CI: 2.714.4) and less frequently C4 hypocomplementemia and peripheral neuropathy.
Conclusion: pSS-CV has a severe clinical course, overshadowing the typical clinical manifestations of pSS and
higher risk for early lymphoma development compared to HCV related CV. Though infrequent, pSS-CV con-
stitutes a distinct severe clinical phenotype of pSS.
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Cryoglobulinemic vasculitis (CV) is a life threatening immune com-
plex mediated small vessel vasculitis, involving primarily the skin, kid-
neys, and peripheral nerves, leading to end stage organ/tissue damage,
if untreated [1,2]. It can be of infectious origin, with hepatitis C virus
(HCV) infection being the most common cause, or associated with
autoimmune diseases where the most frequent underlying condition
is primary Sj€ogren’s syndrome (pSS). As new, effective therapeutic
modalities for the management of HCV infection keep emerging, pSS
will soon become the leading cause of CV [2,3]. CV is associated with
the presence of serum cryoglobulins of which, type II containing an
IgMk monoclonal rheumatoid factor (mRF) predominate in pSS, while
both type II and III are detected in HCV and other autoimmune dis-
eases. Previous studies have clearly shown that type II cryoglobuline-
mia in pSS is associated with more systemic manifestations, mainly
vasculitis [4], and higher risk for future lymphoma development [5].
Thus, cryoglobulinemia is at the crossroad of the two most serious
complications of pSS, that is, systemic vasculitis and B-cell non- Hodg-
kin’s lymphoma (NHL). With the advent of new treatments, targeting
successfully B-cells and NHL [6], the investigation and mapping of the
clinical spectrum of pSS-CV may provide a concise strategic plan for
early diagnosis and treatment for this subset of pSS. To this end, older
studies have described the clinical picture of pSS patients in associa-
tion with cryoglobulinemia [79], while after the introduction of CV
criteria [10,11] some studies have focused on CV [1216]. However,
even after the application of CV classification criteria, the clinical pic-
ture of pSS-CV is still obscured due to the fact that many of the previ-
ous studies have a small number of pSS patients.
Herein, we present the clinical phenotype of CV in an integrated
study population of Greek-Italian pSS patients, investigate the possi-
ble role of CV and cryoglobulinemia in NHL development in pSS and
compare the clinical manifestations of pSS-CV with HCV-CV.
Patients and methods
Study design
This is a retrospective, matched case-control study in a multicen-
ter population of consecutive pSS patients who fulfilled the
2016 ACR/EULAR classification criteria [17] and were followed up
from May 1984 until March 2019, in 5 centers from Greece and Italy
(University of Udine, Pisa, Athens, Harokopio, Ioannina) (UPAHI
group). The study was approved by the local ethical committees of all
the Institutions involved, after obtaining patients’ informed consent
and in compliance to general data protection regulations (GDPR).
One thousand eighty-three patients had been evaluated for serum
cryoglobulins and 71 of them fulfilled the 2011 classification criteria
for CV [10]. Cryoglobulins were evaluated after blood collection,
quantitation, immunodiffusion and immunofixation, as described
previously [4]. All pSS patients were HCV-RNA negative. The cumula-
tive clinical, laboratory and histologic data of pSS-CV patients were
compared with two control groups: a) pSS patients, repeatedly nega-
tive for serum cryoglobulins, matched (1:2 ratio) according to gender,
age at pSS onset and disease duration from pSS onset and b) patients
with HCV related CV, being RNA positive at CV diagnosis and without
any associated autoimmune rheumatic disease, matched (1:1)
according to age and gender. All patients with HCV related CV were
diagnosed, treated and followed-up at the Infectious Disease Unit,
Department of Clinical and Biomedical Sciences Hospita L. Sacco,
Milan, Italy. In addition, pSS cryoglobulin-positive patients who did
not fulfill the 2011 CV classification criteria, were compared with a
pSS cryoglobulin negative control group, matched (1:2 ratio) accord-
ing to gender, age and disease duration from pSS onset. All the labo-
ratory, objective tests or minor salivary gland biopsy of pSS patients,
were performed in the context of standard of care, according tophysicians’ judgment. pSS onset was defined as the year when the
patient recalled the first disease related manifestation, such as Ray-
naud’s phenomenon, arthritis, sicca symptoms, salivary gland
enlargement or purpura. CV onset was defined as the time point of
the appearance of the first CV related manifestation, according to the
2011 classification criteria. Groups were compared on the basis of
cumulative clinical (dry mouth, dry eyes, salivary gland enlargement,
Raynaud’s phenomenon, lymphadenopathy, arthralgia/myalgia,
arthritis, palpable purpura, liver involvement, kidney involvement,
central and peripheral nervous system involvement, lymphoma), lab-
oratory (anti Ro/SSA antibodies, anti La/SSB antibodies, rheumatoid
factor, cryoglobulinemia, low serum C4 complement levels, monoclo-
nal gammopathy) and histologic (focus score, germinal centers) fea-
tures. Systemic organ involvement was based on the ESSDAI
definitions and/or biopsy specimens [18]. Fatigue, dryness and pain
were assessed as defined by the ESSPRI [19]. Since different pathoge-
netic mechanisms are operating in glandular and extraglandular
manifestations of pSS, they have been classified as glandular (dry
mouth, dry eyes, salivary gland swelling), non-specific manifestations
(fatigue, arthralgia/myalgia, arthritis, Raynaud΄s phenomenon),
peri‑epithelial (interstitial nephritis, primary biliary cholangitis, small
airways disease), immune complex mediated (extra-epithelial) (pur-
pura, skin ulcers, glomerulonephritis, vasculitic involvement of
peripheral and/or central nervous system) and NHL [20].
Statistical and data driven analysis
Statistical analysis for categorical data was performed by x2 test
with Yates correction or Fisher exact when cell counts <5 patients and
for numerical data t-test or Mann-Whitney, after Shapiro-Wilk nor-
mality test. In order to handle the multiple comparison testing, p-val-
ues have been also adjusted with Bonferroni correction. The Fast-
Correlation based feature selection (FCBF) algorithm was applied on
the dataset of pSS-CV patients and their pSS cryoglobulin negative con-
trols, to identify potentially independent variables associated with
lymphoma [21]. The FCBF preselection algorithm is a correlation based
tool identifying, among several potentially independent variables,
those with the weakest association amongst them and the strongest
correlation with the outcome of interest that is NHL. Subsequently, the
strongest preselected group of the FCBC derived potentially indepen-
dent variables, has been used for constructing a binary multivariable
logistic regression model to identify independent variables/features
associated with lymphoma. The implementation of the FCBF-based
multivariable logistic regression approach along with the statistical
analysis was performed using Python 3.6 and GraphPad 7.0a.
Based on the post hoc sample size and study power calculation
conducted according to the Fleiss method, assuming 90% study power
and 95% two-sided levels of confidence, the present study sample
size could detect an effect size (Odds Ratio) of 5.00 between patient
groups (EpiInfo, CDC, Atlanta, Georgia, USA).
Results
Patient characteristics
Serum cryoglobulins were detected in 115/1083 patients (10.6%)
of whom 71 (61.7%) fulfilled the 2011 CV classification criteria, while
44 (38.3%) had pSS with cryoglobulinemia but did not meet the CV
criteria. Early ( 35 years) pSS onset had 19.7% (n = 14/71) of pSS-CV
patients, while 12.7% (n = 9/71) had late ( 65 years) pSS onset.
Among pSS-CV patients, 97% were females (n = 69/71) and 3% males
(n = 2/71). The median age of pSS-CV patients, calculated at pSS onset,
was 50 years (range: 2175). The median duration from pSS onset in
pSS-CV patients was 16 years (range: 037). None of the pSS or RNA-
HCV positive control patients fulfilled criteria for another systemic
autoimmune disease. pSS cryoglobulin positive patients without
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4.5%, (n = 2/44)] with a median age at pSS onset of 50 years (range:
1179) and median disease duration from pSS onset of 13 years
(range: 042).
The clinical phenotype of pSS-cryoglobulin positive patients with and
without CV
The clinical picture of 71 pSS-CV patients was compared with that
of 141 pSS cryoglobulin negative matched control patients. pSS-CV
patients exhibited higher frequency of fatigue (59.2% vs 43%,
p = 0.041, OR = 1.92, 95% CI: 1.083.52), Raynaud’s phenomenon
(47.9% vs 32.6%, p = 0.044, OR = 1.89, 95% CI: 1.063.39), salivary
gland enlargement (53.6% vs 33.3%, p = 0.007, OR = 2.31, 95% CI:
1.294.21) and interstitial renal disease (10% vs 1.5%, p = 0.007,
OR = 7.55, 95% CI: 1.5936.4), compared to pSS-cryoglobulin negative
patients respectively. No difference was found in sicca manifestations
between the 2 groups. As anticipated, pSS-CV patients had increased
prevalence of extra-epithelial manifestations of a vasculitic origin,
including purpura (90.1% vs 14.9%, p < 0.0001, OR = 52.24, 95% CI:
21.43125.4), vasculitic ulcers (12.7% vs 0.71%, p < 0.001, OR = 20.32,Table 1
Comparison of clinical, laboratory and histologic featu
ative serum cryoglobulins.
pSS-CV
Number of patients 71
Gender (female%)(n) 97.2 (69/71)
Disease duration 16 (range: 036)
( from SS onset _years)
Media age (years) 50 (range: 2175)
Clinical Features% (n)
Dry mouth 97.2 (69/71)







Raynaud's phenomenon 47.9 (34/71)
Purpura 90.1 (64/71)









Small airways disease 13(7/54)
Kidney





Focus score (median) 2.05 (34/71)





Low C4 88.6 (62/70)
Hypergammaglobulinemia 69.7 (46/66)
Monoclonal gammopathy 45.5 (30/66)
Leukopenia 17.4 (12/69)
Thrombocytopenia 3(2/67)
Cryo: cryoglobulinemia, SGE: salivary gland enlargem
tral nervous system, AIH: autoimmune hepatitis, PBC
disease, RF: rheumatoid factor.
*: Bonferroni adjusted p-value.95% CI: 3.17224.4), peripheral nervous system vasculitic involve-
ment (25.4% vs 1.5%, p < 0.0001, OR = 21.74, 95% CI: 5.1296.01), glo-
merulonephritis, mainly of membranoproliferative type, (11.4% vs
0.71%, p < 0.001, OR = 18.06, 95% CI: 2.64201.8) and lymphadenop-
athy (31% vs 7.1%, p < 0.001, OR = 5.88, 95% CI: 2.6312.99). NHL,
mainly of MALT type, was more frequent in the pSS-CV group (47.9%
vs 8.5%, p < 0.0001, OR = 9.87, 95% CI: 4.720.9). Minor salivary gland
biopsies of pSS-CV patients displayed a higher proportion of germinal
centers (35% vs 11.3%, p = 0.043, OR = 4.21, 95% CI: 1.2013.45) and a
higher focus score [median: 2.05 (range: 09) vs 1.45 (range: 07)]
compared to pSS cryoglobulin negative controls. The laboratory anal-
ysis disclosed that almost all pSS-CV patients had positive rheuma-
toid factor (95.7% vs 61.3, p < 0.0001, OR = 14.09, 95% CI:
4.5844.33) as well as low C4 complement levels (88.6% vs 31.5,
p < 0.0001, OR = 16.82, 95% CI: 7.4735.57). Monoclonal gammop-
athy was also more prevalent in the pSS-CV group (45.5% vs 7.6%,
p < 0.0001, OR = 10.17, 95% CI: 4.4122.17). The presence of anti-Ro/
SSA and anti-La/SSB autoantibodies was comparable between the
two groups. A more detailed comparison of the clinical, laboratory,
serological and histologic features between the 2 groups are pre-
sented in Table 1. After applying Bonferroni correction, fatigue,res between pSS-CV and pSS patients with neg-
pSS-Cryo negative P-value P-value*
141
96.5 (136/141) 1 1
15 (range: 034) 0.720 1
50 (range: 2077) 0.887 1
93.6 (132/141) 0.342 1
92.9 (131/141) 0.104 1
33.3 (47/141) 0.007 0.252
7.1 (10/141) <0.0001 <0.001
43(55/128) 0.041 1
63.8 (90/141) 0.312 1
18.3 (23/126) 0.295 1
1.4 (2/141) 0.552 1
32.6 (46/141) 0.044 1
14.9 (21/141) <0.0001 <0.0001
0.71 (1/141) <0.001 0.009
1.5 (2/130) <0.0001 <0.0001
2.3 (3/129) 1 1
0(0/141) 1 1
1.4 (2/141) 1 1
2.8 (4/141) 0.666 1
6.8 (9/133) 0.853 1
6.6 (8/121) 0.273 1
1.5 (2/138) 0.007 1
0.71 (1/141) <0.001 0.026
10.8 (8/74) 0.260 1
8.5 (12/141) <0.0001 <0.0001
1.42 (78/141) 0.025 0.9
11.3 (6/53) 0.043 1
85(119/140) 0.429 1
46(64/139) 0.078 1
83.6 (117/140) 0.472 1
61.3 (84/137) <0.0001 <0.0001
31.5 (41/130) <0.0001 <0.0001
56.9 (74/130) 0.114 1
7.6 (10/132) <0.0001 <0.0001
10 (14/140) 0.193 1
2.2 (3/134) 1 1
ent, PNS: peripheral nervous system, CNS: cen-
: primary biliary cirrhosis, ILD: interstitial lung
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disease, focus score and germinal centers were found with no statisti-
cally significant difference between the 2 groups (Table 1).
The FCBF algorithm, that constitutes the data driven analytic
approach, performed analysis of 36 features/variables and disclosed 8
strong potentially independent variables [lymphadenopathy, cryo-
globulinemia, positive rheumatoid factor (RF), salivary gland enlarge-
ment (SGE), dry mouth, arthritis, CNS involvement and lung-
bronchocentric involvement accounting for small airways disease].
Narrowing of the analysis, using a combined FCBF/multivariable
logistic regression model, showed that lymphadenopathy, cryoglobu-
linemia and positive RF are independent lymphoma associated fea-
tures (supplementary Table 1). The performance of the model
disclosed 70.6% sensitivity, 94.7% specificity and 84.5% accuracy area
under the curve (AUC = 85.5%), after a 10-fold cross validation
approach (supplementary Figure 1).
The most common presenting manifestations, according to the
2011 CV classification criteria, of pSS-CV patients were arthralgia/
myalgia (49%), followed by arthritis (43.7%) and purpura (39.1%)
(Fig. 1A). More than half of the patients (58.2%) with CV developed
the first CV specific manifestation within the first year of pSS onset
(Fig. 1B). In one third of pSS-CV patients (33.3%), lymphoma was
observed within 5 years of CV onset, while in 13.3% of them, the
appearance of lymphoma was a late sequel (>15 years of CV dura-
tion) (Fig. 1C).Fig. 1. The clinical course1A) Most common presenting clinical manifestations of CV after
applying the 2011 CV classification criteria, 1B) Chronological presen-
tation of first CV related manifestation after pSS onset, 1C) Time dis-
tribution of lymphoma development during the course of CV.
The comparison between pSS cryoglobulin positive patients with-
out CV and pSS cryoglobulin negative controls is presented in Table 2.
The pSS cryoglobulin positive group without CV, had a higher fre-
quency of monoclonal gammopathy (22% vs 7.3%, p = 0.040,
OR = 3.56, 95% CI: 1.1611.16) and NHL (29.5% VS 5.9%, P<0.001,
OR = 6.26, 95% CI: 2.1317.67). Data regarding lymphoma and type
of cryoglobulins were available in 27 of 44 pSS cryoglobulin positive
patients without CV. Type II cryoglobulinemia, containing an IgMk
monoclonal RF, was present in 87.5% (n = 7/8) of pSS patients with
lymphoma and 47.3% (n = 9/19) in those without, while type III cryo-
globulinemia was more prevalent in non-lymphoma (52.7%, n = 10/
19) compared to lymphoma (12.5%, n = 1/8) pSS patients. After Bon-
ferroni adjustment, monoclonal gammopathy was found with no sta-
tistically significant difference between the 2 groups (Table 2).
Overall, the 71 pSS-CV patients with either mild/non-specific or
serious manifestations were treated as follows: corticosteroids (CS)
86%, hydroxychloroquine (HCQ) 80.3%, azathioprine (AZA) 21.1%,
methotrexate (MTX) 22.5%, cyclophosphamide (CyC) 8.5%, rituximab
(RTX) 18.3% and plasmapheresis 7%. Notably, pSS-CV patients with-
out lymphoma received more frequently AZA, MTX and CyC com-
pared to those with lymphoma (32.4% vs 8.8%, 27% vs 17.6% andof pSS-CV patients.
Table 2
Clinical, laboratory and histologic features of cryoglobulin positive pSS patients without CV compared to pSS cryoglobulin
negative patients.
pSS-Cryo without CV pSS-Cryo negative P-value P-value*
Number of patients 44 84
Gender (female )% (n) 95.5 (42/44) 95.2 (80/84) 0.700 1
Median age (years) 50 (range:1179) 51 0.695 1
Median disease duration (from SS onset _years) 13 (range:042) 11.5 0.628 1
Clinical features% (n)
Dry mouth 95.5 (42/44) 95.2 (80/84) 1 1
Dry eyes 97.7 (43/44) 95.2 (80/84) 0.659 1
SGE 48.8 (21/43) 29.8 (25/84) 0.054 1
Lymphadenopathy 13.6 (6/44) 6 (5/84) 0.253 1
Fatigue 36.8 (14/38) 43.6 (37/80) 0.444 1
Arthralgia/myalgia 56.8 (25/44) 53.6 (45/84) 0.870 1
Arthritis 10.8 (4/38) 8.9 (7/79) 0.746 1
Myositis 0 (0/44) 0 (0/84) 1 1
Raynaud's phenomenon 38.6 (17/44) 28.6 (24/84) 0.337 1
Purpura 6.8 (3/44) 15.5 (13/84) 0.253 1
Vasculitic ulcer 2.3 (1/44) 1.2 (1/84) 1 1
PNS 4.5 (2/44) 3.6 (3/82) 1 1
CNS 2.3 (1/44) 2.4 (2/82) 1 1
Liver
Sclerosing Cholangitis 0 (0/44) 2.4 (2/784) 0.545 1
AIH 0 (0/44) 0 (0/84) 1 1
PBC 0(0/42) 3.6 (3/84) 0.550 1
Lung
ILD 9.1 (4/44) 4.9 (4/81) 0.450 1
Small airways disease 0 (0/40) 6.5 (5/77) 0.163 1
Kidney
Interstitial renal disease 4.5 (2/44) 1.2 (1/83) 0.275 1
Glomerulonephritis 2.3 (1/44) 1.2 (1/83) 1 1
Splenomegaly 0 (0/44) 0 (0/84) 1 1
Lymphoma 29.5 (13/44) 6(5/84) <0.001 0.023
Biological features% (n)
Anti-Ro/SSA 70.5 (31/44) 71.4 (60/84) 0.928 1
Anti-La/SSB 25 (11/44) 41.7 (35/84) 0.094 1
RF 70.7 (29/41) 53(44/83) 0.090 1
Low C4 53.6 (22/41) 36.3 (29/80) 0.100 1
Hypergammaglobulinemia 59(23/39) 55(44/80) 0.831 1
Monoclonal gammopathy 22 (9/41) 7.3 (6/82) 0.040 1
Leukopenia 4.5 (2/44) 8.3 (7/84) 0.717 1
0.122 1
Cryo: cryoglobulinemia, SGE: salivary gland enlargement, PNS: peripheral nervous system, CNS: central nervous system,
AIH: autoimmune hepatitis, PBC: primary biliary cirrhosis, ILD: interstitial lung disease, RF: rheumatoid factor.
*: Bonferroni adjusted p-value.
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have received: CS 31.4%, HCQ 46.4%, AZA 4.3%, MTX 7.1%, CyC 0.7%
and RTX 4.3%. Interestingly, pSS-CV patients with serious manifesta-
tions such as glomerulonephritis, peripheral neuropathy and vascu-
litic ulcers were treated with steroids, hydroxychloroquine, B cell
depletion therapy and very few cases with cyclophosphamide or
plasmapheresis. A more detailed description of treatment is pre-
sented in supplementary Table 2. The therapeutic regimen of the 44
cryoglobulin positive without CV pSS patients versus (vs) their con-
trols included: CS 38.6% vs 39%, HCQ 45.5% vs 65.9%, AZA 9.1% vs
6.1%, MTX 2.3% vs 7.3%, CyC 4.5% vs 2.4% and RTX 4.5% vs 8.5% (sup-
plementary Table 3).
Comparison of pSS-CV vs HCV-CV patients
The differences between the 71 pSS-CV and the 76 HCV-CV
matched patients are presented in Table 3. As expected, dry eyes
(98.6% vs 21.1%, p < 0.0001, OR = 262.5, 95% CI: 42.142680), dry
mouth (97.2% vs 18.4%, p < 0.001, OR = 152.8, 95% CI: 34.41657.8)
and salivary gland enlargement (53.6% vs 0%, p < 0.0001) were more
frequent among pSS-CV patients compared to HCV-CV. In addition,
lymphadenopathy (31% vs 4%, p < 0.001, OR = 10.78, 95% CI:
3.2935.17), arthritis (25.7% vs 10.8%, p = 0.035, OR = 2.85, 95% CI:
1.176.86), Raynaud΄s phenomenon (47.9% vs 22.4%, p = 0.002,
OR = 3.18, 95% CI: 1.596.45), interstitial renal disease (10% vs 1.4%,p = 0.030, OR = 8.11, 95% CI: 1.3692.47), hypergammaglobulinemia
(69.7% vs 26.2%, p < 0.001, OR = 6.49, 95% CI: 2.9813.41) and type II
IgMk cryoglobulinemia (97% vs 80.3%, p = 0.035, OR = 7.86, 95% CI:
1.1585.55) were more often observed in pSS-CV compared to HCV-
CV patients. On the contrary, HCV infection was associated with
increased frequency of fatigue (98.6% vs 59.2%, p < 0.0001,
OR = 47.64, 95% CI: 8.18495.9), peripheral nervous system vasculitic
involvement (71.6% vs 25.4%, p < 0.0001, OR = 7.43, 95% CI:
3.5915.57) and low C4 (98.5% vs 88.6%, p = 0.033, OR = 8.51, 95% CI:
1.2295.82), compared to pSS. The prevalence of lymphoma devel-
opment was significantly higher in pSS-CV compared to HCV-CV
patients (47.9% vs 13%, p < 0.0001, OR = 6.12, 95% CI: 2.714.4). After
Bonferroni correction, arthritis, Raynaud’s phenomenon, interstitial
renal disease, low C4 and type II cryoglobulinemia were found with
no statistically significant difference between the 2 groups (Table 3).
Discussion
Cryoglobulinemic vasculitis is a rare disease presenting in approx-
imately 411% of pSS patients [16,22,23]. Despite the rarity, the dis-
ease exhibits two major clinical elements leading to poor outcome in
pSS, which are systemic vasculitis and lymphoma development. This
information has been concluded by several case and cohort studies in
the past [4,16,2325]. However, the major determining factor of
those studies was the presence of cryoglobulinemia while more
Table 3
Comparison of the clinical, laboratory and histologic features between pSS-CV and HCV-SS patients.
pSS-CV HCV-CV P-value P-value*
Number of patients 71 76
Gender (female )% (n) 97.2 (69/71) 97.4 (74/76) 1 1
Median age (years) 50 (range: 2175) 51 (range: 2962) 0.718 1
Clinical Features% (n)
Dry mouth 97.2 (69/71) 18.4 (14/76) <0.0001 <0.0001
Dry eyes 98.6 (70/71) 21.1 (16/76) <0.0001 <0.0001
SGE 53.6 (37/69) 0(0/75) <0.0001 <0.001
Lymphadenopathy 31 (22/71) 4(3/75) <0.0001 <0.001
Fatigue 59.2 (42/71) 98.6 (69/70) <0.0001 <0.0001
Arthralgia/myalgia 71.8 (51/71) 73.7 (56/76) 0.797 1
Arthritis 25.7 (18/70) 10.8 (8/74) 0.035 1
Myositis 0(0/71) 0(0/75) 1 1
Raynaud's phenomenon 47.9 (34/71) 22.4 (17/76) 0.002 0.062
Purpura 90.1 (64/71) 88.2 (67/76) 0.902 1
Vasculitic ulcer 12.7 (9/71) 25(19/76) 0.090 1
PNS 25.4 (18/71) 71.6 (53/74) <0.0001 <0.0001
CNS 2.8 (2/71) 1.4 (1/71) 1 1
Liver
Sclerosing Cholangitis 0(0/71) 0(0/76) 1 1
AIH 1.4 (1/71) 0(0/70) 1 1
PBC 1.4 (1/71) 0(0/72) 0.496 1
Lung
ILD 8.6 (6/70) 1.3 (1/75) 0.056 1
Small airways disease 13 (7/54) 4(3/75) 0.093 1
Kidney
Interstitial renal disease 10 (7/70) 1.4 (1/74) 0.030 0.93
Glomerulonephritis 11.4 (8/70) 23.7 (18/76) 0.085 1
Splenomegaly 2.8 (2/71) 10.8 (8/74) 0.097 1
Lymphoma 47.9 (34/71) 13(9/69) <0.0001 <0.001
Biological features% (n)
RF 95.7 (67/70) 87.1 (61/70) 0.128 1
Low C4 88.6 (62/70) 98.5 (66/67) 0.033 1
Cryoglobulinemia type II 97 (32/33) 80.3 (61/76) 0.035 1
Hypergammaglobulinemia 69.7 (46/66) 26.2 (17/65) <0.0001 <0.0001
Monoclonal gammopathy 45.5 (30/66) 55.5 (20/36) 0.442 1
Leukopenia 17.4 (12/69) 14.7 (10/68) 0.845 1
Thrombocytopenia 3(2/67) 11.4 (8/70) 0.097 1
SGE: salivary gland enlargement, PNS: peripheral nervous system, CNS: central nervous system, AIH:
autoimmune hepatitis, PBC: primary biliary cirrhosis, ILD: interstitial lung disease, RF: rheumatoid
factor.
*: Bonferroni adjusted p-value.
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tion criteria for CV are limited [9,10,14,16,26,27]. Thus, the clinical
presentation of pSS-CV, as well as the characteristics that rule the
outcome and the definition of the clinical phenotype of pSS-CV are
still unmet needs.
The present study was conducted to address the clinical presenta-
tion of CV in unselected patients with pSS. The tools that were used
include: a) an integrated Greek-Italian population, from 5 clinical
centers evaluated by physicians, highly experienced with pSS-CV, b)
application of unified and validated criteria for both pSS and CV, c)
carefully selected triple matched 1:2 controls from the same clinical
center, and d) analysis of the results by applying not only the classic
statistics, but beyond that, a data driven approach with an unbiased
selection of variables, to point out features associated with CV which
are involved in lymphoma development. HCV infection often mimics
pSS, sharing common clinical manifestations, including sicca symp-
toms and CV. To address this challenging diagnostic question, we
compared the clinical picture of pSS-CV with that of HCV-CV.
To our knowledge this is the largest study of pSS-CV patients ful-
filling the 2011 CV classification criteria. The prevalence of cryoglo-
bulins is within the range reported by previous studies, [79,14,16]
corresponding to 10% of the evaluated pSS patients. The clinical pic-
ture described in this report is in line with previous studies, but some
points are presented for the first time and deserve special attention:
a) approximately 60% of pSS-CV patients had their first CV manifesta-
tion within the first year from pSS onset, b) pSS-CV is heralded bynon-specific clinical manifestations, such as arthralgia/myalgia,
arthritis or Raynaud’s phenomenon, c) high prevalence of skin vascu-
litis, extending from the one third of patients at disease onset to
almost all patients after many years of follow up and d) a time-
related pattern for the appearance of glomerulonephritis and periph-
eral neuropathy was not observed. One-third of the associated NHL
cases occurred during the first 5 years after CV onset, but the diagno-
sis of NHL for the majority of pSS-CV patients, spread out in 20 years,
since CV diagnosis. Based on these observations, since pSS-CV is usu-
ally heralded by non-specific manifestations of pSS, it is strongly rec-
ommended that, pSS patients must be evaluated properly at pSS
onset for the presence of cryoglobulins. Following early diagnosis,
pSS-CV patients should undergo a close follow up for many years,
since internal organ vasculitis or lymphoma can very well be late
sequels. These findings can also start a discussion, whether early
intervention with targeted B-cell treatments, might be instituted
after the detection of cryoglobulins, even if this is associated with
non-specific symptoms, in an attempt to prevent overt vasculitis
and/or lymphoma. Finally, the present study has clearly shown that
pSS-CV and HCV-CV, are distinct entities, since pSS-CV patients pres-
ent much more frequently with sicca manifestations, lymphadenopa-
thy, arthritis and lymphoma, mainly in the context of type II
cryoglobulinemia with an IgMkmRF [28].
In accordance with previous reports [16,26,29], purpura is the
most prevalent CV-specific manifestation of pSS-CV. This study, adds
that purpura is also the most common CV-specific presenting
852 O.D. Argyropoulou et al. / Seminars in Arthritis and Rheumatism 50 (2020) 846853manifestation occurring in one-third of patients within the first year
after pSS onset, thus explaining why purpura at pSS diagnosis is an
excellent predictor for future lymphoma development [30]. Although
the clinical expression of pSS-CV is spreading across time, this study
showed a temporal clustering of CV and pSS onset in 60% of pSS-CV
patients. In line with this, one third of pSS-CV will eventually develop
a non-Hodgkin lymphoma of B cell origin within the first 5 years of
pSS onset. Taken together, it appears that this subset of pSS patients
possess a discrete B cell monoclonal population, producing an IgMk
monoclonal RF, very early during pSS disease course. Importantly,
previous data point out that the monoclonal component is composed
within the salivary glands [31,32], explaining why salivary gland
enlargement in several reports is an independent predictor of future
lymphoma development. The production and perpetuation of mRFs
within the inflamed salivary glands are probably attributed to the
formation of ectopic germinal center like structures (EGCS), which
are more frequently found in pSS-CV patients compared to cryoglo-
bulin negative controls. On the contrary, in HCV-related cryoglobuli-
nemia [12], B-cell clonal expansion is mainly localized within the
bone marrow and the liver [33]. Compared to HCV-CV, pSS-CV
patients carry an increased risk of lymphoma that could be explained
by the occurrence of MALT lymphomas unrelated to cryoglobuline-
mia [12] and by the more intense and persistent autoreactive B cell
activation as attested by the higher frequency of lymphadenopathy,
hypergammaglobulinemia and specific autoantibodies, observed in
pSS-CV patients. On the other hand, HCV-CV patients had a remark-
ably increased peripheral nervous system involvement which could
be attributed to 2 distinct underlying mechanisms: a) inflammation
of the vasa nervorum not only due to cryoglobulins but also to anti-
HCV/HCV immune complex deposition, and b) direct HCV mediated
inflammation of the nerves [3436].
Previous studies have clearly shown that cryoglobulinemia is
associated with increased morbidity and mortality, serving also as
one of the strongest laboratory predictors for future lymphoma
development, either with or without CV [13,30,37]. The answer to
the question whether cryoglobulinemia or CV serves better as lym-
phoma risk factor is still unaddressed. Indeed, previous studies, using
small number of patients, showed that neither CV nor cryoglobuline-
mia were proven risk factors for lymphoma in the multivariate
model, although CV was correlated with increased mortality [16]. In
our dataset, we performed a data driven analysis to identify lym-
phoma associated features including both cryoglobulinemia and the
presence of CV. Although, cryoglobulinemia was emerged as an inde-
pendent feature, this finding is random, since in our specific dataset
both cryoglobulinemia and CV possess the same power of signifi-
cance, according to the FCBC algorithm and, eventually one of them,
but not both could be selected as a potentially independent variable.
The FCBF algorithm categorizes on a mathematical based manner,
features and variables with minimal inter-correlation and therefore
it was unexpected to pre-select both cryoglobulinemia and CV as
potentially independent variables for the logistic regression (LR)
model. Thus, it was highly unlikely to compare cryoglobulinemia and
CV as independent variables for any type of LR model, since the first
variable is a prerequisite for the second. Finally, to address this ques-
tion, we analyzed concomitantly the group of the 44 pSS cryoglobulin
positive patients without vasculitic tissue damage and compared it
with the 71 pSS CV patients. Around half of the pSS-CV patients had
NHL, while that was true only for one fourth of cryoglobulin positive
CV negative pSS patients. In the latter group the determining factor
for lymphoma development was the presence of mRF in the cryopre-
cipitate (87.5% of patients with lymphoma) i.e. type II cryoglobuline-
mia and not type III. In the pSS-CV patients where the prevalence of
lymphoma was double, the presence of IgMkmRF type II cryoglobuli-
nemia was 97%. At this point, we feel it is important to emphasize
that the capacity of serum cryoglobulins to precipitate in tissues may
be affected by many factors: a) the quantity of circulatingcryoglobulins as a net balance between production and clearance
[38,39], b) the degree of the affinity-avidity of the monoclonal com-
ponent with rheumatoid factor activity against the polyclonal IgG
component [40], c) the physicochemical properties of cryoglobulins
such as sialylation of the Fc portion [41] and d) several environmental
factors including temperature, pH and the presence of plasma hyper-
filtration conditions in specific tissues [40,42]. Thus, the cryoprecipit-
able IgMk mRF, the common denominator between the two groups,
operates as either a double or single sword edge in patients with
pSS-CV and pSS with cryoglobulinemia only, regarding lymphoma
development. In the second case, it represents only the B-cell clonal
expansion, whilst in the first case it is the major element responsible
for the generation of the complex disease of CV that can be seen as a
composite index, born by nature. This can explain why in several pre-
vious studies, many items of CV served as predictive factors for future
lymphoma development. Another issue that remains inadequately
addressed in the literature, is the net effect of specific treatment
modalities on lymphoma development. In this series of pSS-CV
patients, the majority of those with severe vasculitic involvement
were treated with corticosteroids, hydroxychloroquine, B cell deple-
tion therapy (rituximab) and plasmapheresis. In very few cases cyclo-
phosphamide was administered, while methotrexate (MTX) and
azathioprine (AZA) were more commonly used in pSS-CV patients
compared to cryoglobulin negative controls. pSS-CV patients without
lymphoma have been also treated more frequently with MTX and
AZA compared to those with lymphoma. Therefore, it seems that the
additional risk from the excess use of MTX and AZA among pSS-CV
patients compared to controls is low, suggesting that systemic immu-
nosuppression confers low risk to lymphoma development.
In this work, we present our results with and without Bonferroni
correction that represents one of the most widely used methods for
p-values adjustment to avoid type I error in the context of multiple
comparisons. However, it has been supported that Bonferroni correc-
tion is very stringent and augments the occurrence of type II error
[43]. Therefore, many researchers including the authors of this manu-
script, choose not to make any adjustments for multiple comparisons
and present data on the original form [43], while part of the scientific
community believes that Bonferroni correction is of limited use in
biomedical science [44]. For all reasons mentioned above, we show
the original and Bonferroni adjusted p-values, adopting in this way
all scientific opinions. At the end, CV was proven a major risk factor
for lymphoma development. The statistical significance of this ele-
ment was not lost after Bonferroni correction, a finding that further
strengthens our conclusions. On the other hand, the non-specific fea-
tures of CV such as Raynaud’s phenomenon and fatigue did not retain
statistical significance after adjustment, implying that a type II error
may have occurred.
The current study has some limitations. Even if the group of pSS-
CV patients is the largest ever described, its number is still relatively
small and therefore, a larger group would allow a better power analy-
sis. While our study was amply powered, the resulting confidence
intervals of effect estimates, support the necessity for the refinement
of exact effect size estimates, in further prospective investigations.
The fact that not all pSS patients included in the total study popula-
tion have been evaluated for cryoglobulins, probably underestimates
the real prevalence of both cryoglobulinemia and CV, pointing out a
selection bias. However, the evaluated pSS patients represent more
serious cases and therefore, our results can be generalized, as they
reflect the real clinical practice. In addition, the inclusion of non-spe-
cific manifestations in the 2011 classification criteria of CV is an inner
deficit, leading to overestimation of such manifestations in the con-
text of pSS CV, since they can be attributed to either the CV or pSS
itself. Such limitations, regarding not only the clinical phenotyping of
CV in pSS but also the need for validation, are expected to be over-
come through a large multicenter study population in the context of
the HarmonicSS project. Another limitation is the heterogeneity in
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between Greek and Italian pSS patients who participated in the study.
Finally, the FCBF/LR data driven analysis was applied on the dataset of
pSS-CV and cryoglobulin negative patients, of whom 46 had lym-
phoma, a relatively small number that is anticipated to affect the sen-
sitivity level of the model.
In summary, CV associated with pSS constitutes a specific clinical
phenotype of pSS, associated with both an inflammatory component,
clinically expressed as vasculitis and NHL development. The presence
and type of cryoglobulins should be evaluated early and during fol-
low up in every patient with pSS. In the majority of patients, CV is
appeared early after pSS onset, with non-specific clinical manifesta-
tions or purpura. The major determining factor of CV is the IgMkmRF
of type II mixed cryoglobulinemia, offering the opportunity to use B-
cell targeted treatments that have the potential to halt the progress
of the disease. Finally, the clinical expression of pSS-CV, has certain
differences compared to HCV related CV, reflecting biologic differen-
ces which may guide the physicians in the differential diagnosis and
the proper therapeutic interventions.
Supplementary materials
Supplementary material associated with this article can be found,
in the online version, at doi:10.1016/j.semarthrit.2020.07.013.
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